Pfizer’s oral alopecia areata (AA) therapy Litfulo (ritlecitinib) will see its NHI price being pared by 218 yen, or 3.8%, in June under the cost-effectiveness assessment (CEA) scheme, a key reimbursement policy panel agreed on March 12. Litfulo’s price will…
To read the full story
Related Article
- Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment
January 30, 2025
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





